{"id":688634,"date":"2022-09-26T07:16:13","date_gmt":"2022-09-26T11:16:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/"},"modified":"2022-09-26T07:16:13","modified_gmt":"2022-09-26T11:16:13","slug":"omega-therapeutics-to-participate-in-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","title":{"rendered":"Omega Therapeutics to Participate in Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">CAMBRIDGE, Mass.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 26, 2022<\/span><\/span> \/PRNewswire\/ &#8212; Omega Therapeutics, Inc. (Nasdaq: OMGA) (&#8220;Omega&#8221;), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming\u2122 platform, today announced that members of management will participate in two upcoming investor conferences.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold\" role=\"heading\">\n        <b>Jefferies Cell and Genetic Medicine Summit <\/b>\n      <\/div>\n<p>Fireside Chat<br \/>Date: <span class=\"xn-chron\">September 30, 2022<\/span><br \/>Time: <span class=\"xn-chron\">9:00 a.m. ET<\/span><\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold\" role=\"heading\">\n        <b>Chardan&#8217;s 6<sup>th<\/sup> Annual Genetic Medicines Conference<\/b>\n      <\/div>\n<p>Gene Regulation Panel<br \/>Date: <span class=\"xn-chron\">October 4, 2022<\/span><br \/>Time: <span class=\"xn-chron\">9:30 a.m. ET<\/span><\/p>\n<p>Fireside Chat<br \/>Date: <span class=\"xn-chron\">October 4, 2022<\/span><br \/>Time: <span class=\"xn-chron\">11:00 a.m. ET<\/span><\/p>\n<p>Live webcasts of the fireside chats and panel discussion will be available on the Investors &amp; Media section of the Company&#8217;s website at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3656686-1&amp;h=3638474305&amp;u=http%3A%2F%2Fwww.omegatherapeutics.com%2F&amp;a=www.omegatherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">www.omegatherapeutics.com<\/a>. An archived replay of the fireside chats will be available on the same website for approximately 90 days.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold\" role=\"heading\">\n        <b>About Omega Therapeutics<\/b>\n      <\/div>\n<p>Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company&#8217;s OMEGA Epigenomic Programming\u2122 platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism&#8217;s life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega&#8217;s process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega&#8217;s modular and programmable mRNA medicines, Omega Epigenomic Controllers\u2122, are designed to target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control\u2122. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.<\/p>\n<p>For more information, visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3656686-1&amp;h=3848756951&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3555300-1%26h%3D1197224379%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3205288-1%2526h%253D853559533%2526u%253Dhttps%25253A%25252F%25252Fomegatherapeutics.com%25252F%2526a%253Domegatherapeutics.com%26a%3Domegatherapeutics.com&amp;a=omegatherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">omegatherapeutics.com<\/a>, or follow us on\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3656686-1&amp;h=2578566305&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3555300-1%26h%3D3977740610%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3205288-1%2526h%253D1522160244%2526u%253Dhttps%25253A%25252F%25252Ftwitter.com%25252FOmegaTX%2526a%253DTwitter%26a%3DTwitter&amp;a=Twitter\" target=\"_blank\" rel=\"nofollow noopener\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3656686-1&amp;h=3097332342&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3555300-1%26h%3D585424183%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3205288-1%2526h%253D1409148463%2526u%253Dhttps%25253A%25252F%25252Fwww.linkedin.com%25252Fcompany%25252Fomega-therapeutics%25252F%2526a%253DLinkedIn%26a%3DLinkedIn&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>Investor and Media Contact:<br \/><\/b>Eva Stroynowski<br \/>617-949-4370<br \/><a href=\"mailto:estroynowski@omegatx.com\" target=\"_blank\" rel=\"nofollow noopener\">estroynowski@omegatx.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder5883\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg\" title=\"(PRNewsfoto\/Omega Therapeutics)\" alt=\"(PRNewsfoto\/Omega Therapeutics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE81615&amp;sd=2022-09-26\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences-301631373.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences-301631373.html<\/a><\/p>\n<p>SOURCE  Omega Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE81615&amp;Transmission_Id=202209260700PR_NEWS_USPR_____NE81615&amp;DateId=20220926\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CAMBRIDGE, Mass. , Sept. 26, 2022 \/PRNewswire\/ &#8212; Omega Therapeutics, Inc. (Nasdaq: OMGA) (&#8220;Omega&#8221;), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming\u2122 platform, today announced that members of management will participate in two upcoming investor conferences. Jefferies Cell and Genetic Medicine Summit Fireside ChatDate: September 30, 2022Time: 9:00 a.m. ET Chardan&#8217;s 6th Annual Genetic Medicines Conference Gene Regulation PanelDate: October 4, 2022Time: 9:30 a.m. ET Fireside ChatDate: October 4, 2022Time: 11:00 a.m. ET Live webcasts of the fireside chats and panel discussion will be available on the Investors &amp; Media section of the Company&#8217;s website at www.omegatherapeutics.com. An archived &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Omega Therapeutics to Participate in Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688634","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Omega Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omega Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CAMBRIDGE, Mass. , Sept. 26, 2022 \/PRNewswire\/ &#8212; Omega Therapeutics, Inc. (Nasdaq: OMGA) (&#8220;Omega&#8221;), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming\u2122 platform, today announced that members of management will participate in two upcoming investor conferences. Jefferies Cell and Genetic Medicine Summit Fireside ChatDate: September 30, 2022Time: 9:00 a.m. ET Chardan&#8217;s 6th Annual Genetic Medicines Conference Gene Regulation PanelDate: October 4, 2022Time: 9:30 a.m. ET Fireside ChatDate: October 4, 2022Time: 11:00 a.m. ET Live webcasts of the fireside chats and panel discussion will be available on the Investors &amp; Media section of the Company&#8217;s website at www.omegatherapeutics.com. An archived &hellip; Continue reading &quot;Omega Therapeutics to Participate in Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-26T11:16:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Omega Therapeutics to Participate in Two Upcoming Investor Conferences\",\"datePublished\":\"2022-09-26T11:16:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"wordCount\":371,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1395202\\\/Omega_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\",\"name\":\"Omega Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1395202\\\/Omega_Therapeutics_Logo.jpg\",\"datePublished\":\"2022-09-26T11:16:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1395202\\\/Omega_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1395202\\\/Omega_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omega Therapeutics to Participate in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omega Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Omega Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk","og_description":"PR Newswire CAMBRIDGE, Mass. , Sept. 26, 2022 \/PRNewswire\/ &#8212; Omega Therapeutics, Inc. (Nasdaq: OMGA) (&#8220;Omega&#8221;), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming\u2122 platform, today announced that members of management will participate in two upcoming investor conferences. Jefferies Cell and Genetic Medicine Summit Fireside ChatDate: September 30, 2022Time: 9:00 a.m. ET Chardan&#8217;s 6th Annual Genetic Medicines Conference Gene Regulation PanelDate: October 4, 2022Time: 9:30 a.m. ET Fireside ChatDate: October 4, 2022Time: 11:00 a.m. ET Live webcasts of the fireside chats and panel discussion will be available on the Investors &amp; Media section of the Company&#8217;s website at www.omegatherapeutics.com. An archived &hellip; Continue reading \"Omega Therapeutics to Participate in Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-26T11:16:13+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Omega Therapeutics to Participate in Two Upcoming Investor Conferences","datePublished":"2022-09-26T11:16:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/"},"wordCount":371,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","name":"Omega Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg","datePublished":"2022-09-26T11:16:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1395202\/Omega_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Omega Therapeutics to Participate in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688634"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688634\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}